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planations for the different mortality results 
of the ERSPC and PLCO trials (3,4).
For this analysis, we used the microsim-
ulation screening analysis (MISCAN) model 
for prostate cancer (5,6), which simulates 
individual life histories and models the 
development of cancer in individuals as a 
sequence of tumor states. The model 
includes 18 detectable preclinical states in 
the natural history of prostate cancer that 
are derived from combinations of clinical T 
stage (T1, impalpable; T2, palpable, con-
fined to the prostate; and T3+, palpable, 
with extensions beyond the prostatic 
capsule) (7), differentiation grade (well dif-
ferentiated, Gleason score 2–6; moderately 
differentiated, Gleason score 7; and poorly 
differentiated, Gleason score 8–10) (8), and 
metastatic stage (local or regional [M0] and 
distant [M1]) (7). Cancer can progress from 
each preclinical state to the clinical disease 
state (ie, become diagnosed because of 
symptoms) (Supplementary Figure 1, avail-
able online). Preclinical cancers may be 
detected by PSA screening. Screen detec-
tion depends on the timing of PSA tests and 
on the test sensitivity. In the MISCAN 
model, the PSA test and a subsequent bi-
opsy are modeled as a single test; therefore, 
PSA test sensitivity also depends on whether 
a positive test is followed by a biopsy. In the 
model, sensitivity is defined as the proba-
bility that a preclinical tumor is detected by 
a screening test at the time the test is taken. 
The parameters for PSA test sensitivity are 
stage specific because the sensitivity of a test 
primarily depends on the size of the tumor.
Model parameters, including transition 
probabilities, mean dwelling times (the 
time from one preclinical state to another 
preclinical or clinical state), and stage- 
specific test sensitivities, are typically esti-
mated as follows. A model is constructed 
for a specific situation, such as prostate 
cancer incidence in the United States or in 
both arms of the ERSPC–Rotterdam. 
Parameters are then estimated by numer-
ical minimization of the deviance between 
observed numbers of cases and the number 
of cases predicted by the model. Deviances 
are calculated by assuming a Poisson likeli-
hood for incidence data or by assuming a 
multinomial likelihood for stage distribution 
data.
Prostate-specific antigen (PSA) testing 
was introduced in the United States in 
1986 to monitor prostate cancer progres-
sion. The test was rapidly adopted for the 
early detection of prostate cancer, and as a 
consequence, the incidence of prostate 
cancer has increased rapidly since 1988, 
peaking in 1992 (1). The benefits and 
harms of PSA testing depend on its per-
formance in detecting prostate cancers 
and on the benefits of consequent early 
treatment. The performance of PSA 
testing as a screening test depends on the 
cutoff level for recommending a biopsy, 
the compliance to a biopsy recommenda-
tion, and the diagnostic accuracy of the 
biopsies that are performed.
Differences between PSA screening per-
formance with respect to the detection of 
prostate cancer in a trial and in a population 
are crucial information for translating the 
results of a prostate cancer screening trial to 
a population setting. In this study, we com-
pared PSA screening performance for 
detecting prostate cancers in the US popu-
lation with that in the Rotterdam section of 
the European Randomized Study of 
Screening for Prostate Cancer (ERSPC–
Rotterdam). Because PSA screening perfor-
mance in the US Prostate, Lung, Colorectal 
and Ovarian (PLCO) trial may be compa-
rable with PSA screening performance in 
the US population (2), the results of this 
analysis could also provide quantitative ex-
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Dissemination of prostate-specific antigen (PSA) testing in the United States coin-
cided with an increasing incidence of prostate cancer, a shift to earlier stage disease 
at diagnosis, and decreasing prostate cancer mortality. We compared PSA screening 
performance with respect to prostate cancer detection in the US population vs in 
the Rotterdam section of the European Randomized Study of Screening for Prostate 
Cancer (ERSPC–Rotterdam). We developed a simulation model for prostate cancer 
and PSA screening for ERSPC–Rotterdam. This model was then adapted to the US 
population by replacing demography parameters with US-specific ones and the 
screening protocol with the frequency of PSA tests in the US population. We as-
sumed that the natural progression of prostate cancer and the sensitivity of a PSA 
test followed by a biopsy were the same in the United States as in ERSPC–
Rotterdam. The predicted prostate cancer incidence peak in the United States was 
then substantially higher than the observed prostate cancer incidence peak (13.3 vs 
8.1 cases per 1000 man-years). However, the actual observed incidence was repro-
duced by assuming a substantially lower PSA test sensitivity in the United States 
than in ERSPC–Rotterdam. For example, for nonpalpable local- or regional-stage 
cancers (ie, stage T1M0), the estimates of PSA test sensitivity were 0.26 in the 
United States vs 0.94 in ERSPC–Rotterdam. We conclude that the efficacy of PSA 
screening in detecting prostate cancer was lower in the United States than in 
ERSPC–Rotterdam.
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In this study, we first developed an 
ERSPC model that simulated the prostate 
cancer progression and screening in 
ERSPC–Rotterdam. Estimates of natural 
history parameters and test sensitivities 
were obtained by using the observed detec-
tion rates, interval cancer rates, and stage 
distributions from ERSPC–Rotterdam 
(5,6). The parameter estimates of the model 
are presented in Supplementary Table 1 
(available online), and the observed data 
used for the estimation are presented in 
Supplementary Table 2 (available online).
Next, to make the model results compa-
rable with observed US data, the popula-
tion in the model was adjusted to the US 
population by replacing the birth tables 
and life tables with US-specific tables, and 
the screening protocol of ERSPC–
Rotterdam was replaced with the frequency 
of PSA testing in the US population. The 
frequency of PSA testing in the United 
States was modeled according to the ap-
proach described by Mariotto et al. (9). 
The frequency of a first PSA test and of 
repeat tests in the United States, as repro-
duced in the MISCAN model, is illustrated 
in Figure 1. On average, 80% of the 
screened men in the United States have a 
repeat PSA test within 2 years of the pre-
vious test.
We considered two US models. In 
model 1, we investigated the hypothesis 
that PSA screening in the United States is 
the same as in ERSPC–Rotterdam. In this 
ConteXt anD CaVeatS
Prior knowledge
The benefits and harms of prostate-specific 
antigen (PSA) testing depend on its perfor-
mance in detecting prostate cancers and on 
the benefits of consequent early treatment. 
The performance of PSA testing as a 
screening test depends on the cutoff level 
for recommending a biopsy, the compli-
ance to a biopsy recommendation, and the 
diagnostic accuracy of the biopsies that are 
performed. Translating the results of a 
prostate cancer screening trial to a popula-
tion setting requires a comparison of PSA 
screening performance for the detection of 
prostate cancer in these two situations.
Study design
A microsimulation screening analysis model 
for prostate cancer and PSA screening was 
developed for the European Randomized 
Study of Screening for Prostate Cancer 
(ERSPC)–Rotterdam trial and then adapted 
to the US population by replacing demogra-
phy parameters with US-specific ones and 
the trial screening protocol with the 
frequency of PSA tests in the US popula-
tion. The natural progression of prostate 
cancer and the sensitivity of a PSA test fol-
lowed by a biopsy were assumed to be the 
same in the United States as in the trial.
Contribution
The model-predicted prostate cancer inci-
dence peak in the United States was sub-
stantially higher than the observed prostate 
cancer incidence peak. However, the actual 
observed incidence was reproduced by 
assuming a substantially lower PSA test 
sensitivity in the United States than in 
ERSPC–Rotterdam.
Implications
PSA screening in the United States detected 
fewer prostate cancers than PSA screening in 
the European trial because of the lower sen-
sitivity of PSA testing followed by biopsy.
Limitations
Other factors that differed between the US 
and ERSPC–Rotterdam populations and 
might influence the detection rates were 
not taken into account. The model used for 
the frequency of PSA testing included diag-
nostic tests. The model did not explain the 
steep drop in prostate cancer incidence in 
the United States after 1992. The reliability 
of the sensitivity estimates could not be 
determined.
From the Editors
 
Figure 1. Frequency of first prostate-specific antigen (PSA) tests and 
repeat tests in the US population as generated by microsimulation 
screening analysis (MISCAN). The frequencies are for men aged 50–84 
years.
model, all prostate cancer–related parame-
ters were the same as in the ERSPC model. 
In model 2, we investigated the hypothesis 
that the sensitivity of PSA screening in the 
United States is lower than that in ERSPC–
Rotterdam. In this model, all prostate cancer– 
related parameters except for the test 
sensitivity parameters were the same as 
those in the ERSPC model. US-specific 
estimates of test sensitivities were obtained 
by using observed age-specific incidence 
and age-specific stage distribution (local or 
regional vs distant) in the US population. 
For estimation of the US-specific parame-
ters, we used data from the Surveillance, 
Epidemiology, and End Results (SEER) 
registry for US men aged 50–84 years who 
were diagnosed with prostate cancer 
between January 1, 1985, and December 
31, 2000. The data were based on the nine 
core catchment areas (SEER 9) of the 
SEER registry (http://seer.cancer.gov/). 
We used the test sensitivity parameter esti-
mates of the ERSPC model as starting 
values for optimization of the estimates of 
the US model. The estimated test sensi-
tivity parameters of the calibrated model 
are presented in Table 1 and the observed 
data used for calibrating the model are pre-
sented in Supplementary Table 3 (available 
online).
In model 1, both the predicted and 
observed incidence peaks occurred in 1992. 
However, the predicted prostate cancer 
incidence peak in the United States was 
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substantially higher than the observed 
prostate cancer incidence peak (13.3 vs 8.1 
cases per 1000 man-years), which suggests 
a lower detection of prostate cancer in the 
United States than in ERSPC–Rotterdam 
(Figure 2). In model 2, the predicted inci-
dence peak was the same size as the observed 
incidence peak (Figure 2). However, esti-
mates of test sensitivity were lower in the 
United States than in ERSPC–Rotterdam. 
For example, for nonpalpable local- or 
regional-stage cancers (ie, stage T1M0), 
the estimates of PSA test sensitivity were 
0.26 in the United States vs 0.94 in 
ERSPC–Rotterdam (Table 1).
The lower sensitivity of PSA screening 
in the United States compared with 
ERSPC–Rotterdam in model 2 could be 
due to a higher PSA cutoff level for recom-
mending biopsy in the United States, a 
lower biopsy compliance rate in the United 
States, or a lower sensitivity of the biopsies 
in the United States. The latter possibility 
is unlikely because more biopsy cores are 
generally taken in the United States than 
were taken in ERSPC–Rotterdam. The 
other two possibilities might explain the 
lower sensitivity of PSA screening in the 
United States. A higher PSA cutoff level 
for recommending biopsy in the United 
States could follow from the fact that the 
recommended PSA cutoff level in the 
United States is 4 ng/mL, whereas the PSA 
cutoff level in ERSPC–Rotterdam was 
3 ng/mL. A lower biopsy compliance rate 
in the United States could, for instance, 
indicate that some physicians in the United 
States might have used a higher PSA cutoff 
level than recommended (ie, higher than 4 
ng/mL) or might have advised a confirma-
tory PSA test if the first PSA level was ele-
vated. Confirmatory PSA tests would lower 
the biopsy compliance rate because men 
with a PSA level higher than the cutoff 
level at the first test but with a PSA level 
lower than the cutoff level at the confirma-
tory test would probably be advised to not 
have a biopsy; therefore, some men with a 
PSA level higher than the cutoff level at the 
first PSA test would not have a biopsy. 
Pinsky et al. (2) reported a biopsy compli-
ance rate in the PLCO trial of 41% within 
1 year of a positive PSA test. They sug-
gested that this biopsy compliance rate is 
representative of US screening practice, 
given that men with a positive PSA test 
in the PLCO trial were referred to their 
Table 1. Estimates of sensitivity, detection rate, and deviance for the two US models*
Item Model 1 Model 2
Sensitivity by stage†
 T1M0 0.94 0.26
 T2M0 0.94 0.26
 T3M0 1.00 0.27‡
 T1M1 0.96 0.84
 T2M1 0.97 0.84
 T3M1 1.00 0.84
Detection rate per 1000 screened men
 At first PSA test 62 18
 At repeat PSA test 13 12
Deviance 44 727 23 438
* PSA = prostate-specific antigen.
† T1, T2, and T3 are the three clinical T stages (T1, nonpalpable; T2, palpable, confined to the prostate; and 
T3, palpable, with extensions beyond the prostatic capsule); M0 is the local or regional stage; and M1 is 
the distant stage.
‡ The range of plausible values is 0.24–0.29. The range of plausible values indicates a range in which 
the 95% confidence interval will be with near certainty, see Supplementary Figure 2 (available online). 
Because of restrictions on the sensitivities (sensitivity increases with clinical T stage and metastatic 
state), this range cannot be calculated for the other parameters.
Figure 2. Observed and predicted age-adjusted incidence per 1000 man-
years for men aged 50–84 years in the US models. In model 1, prostate-
specific antigen (PSA) screening in the US population is the same as in 
the Rotterdam section of the European Randomized Study of Screening 
for Prostate Cancer (ERSPC–Rotterdam). In model 2, the sensitivity of 
PSA screening is lower in the US population than in ERSPC–Rotterdam.
personal physician for follow-up. In the 
screening arm of ERSPC–Rotterdam, bi-
opsies were administered by the screening 
center at no charge to the subject, and re-
minders for biopsy appointments were sent 
if necessary, resulting in a biopsy compli-
ance rate of approximately 90%. In model 
2, the detection rates at first PSA screening 
and at repeat PSA screening were 18 and 
12 per 1000 screened men, respectively 
(Table 1), which are comparable with the 
detection rates at the first round of 
screening (16 per 1000 screened men) and 
repeat screening (11 per 1000 screened 
men) in the PLCO trial (10).
This study has four limitations. First, 
we did not take into account other factors, 
such as race, that differed between the US 
and ERSPC–Rotterdam populations and 
might influence the detection rates. 
Approximately 10% of the US population 
is black, whereas nearly 100% of the 
ERSPC–Rotterdam population was white. 
Because the incidence of prostate cancer 
was higher among black men than among 
white men during the study period (11), 
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these racial differences might explain the 
different detection rates estimated for the 
two populations. However, the incidence 
of prostate cancer among whites in the US 
population was similar to the overall inci-
dence (11), which indicates that the effect 
of black men on the overall observed inci-
dence was small, as was their effect on the 
outcomes of this study.
Second, we assumed that the model that 
we used for the frequency of PSA testing 
(9) would apply to screening tests. During 
the construction of that model, all fol-
low-up PSA tests taken after diagnosis as 
well as PSA tests occurring within 3 months 
of a previous PSA test were eliminated. 
However, a fraction of the remaining tests 
might be diagnostic tests that were used to 
confirm a suspicion for prostate cancer. 
The size of this fraction is unknown, but 
including this fraction of diagnostic tests as 
screening tests would imply that the actual 
screening rate is lower than in the model.
Third, a weakness of our model is that it 
fails to explain why prostate cancer inci-
dence in the United States dropped so 
steeply after 1992 (Figure 2). In our model, 
the cancers detected in repeat tests led to a 
slower decline of incidence after 1992 than 
what was observed. However, the frequency 
of repeat PSA testing remained at a level of 
30% (Figure 1), and it is unclear why these 
tests detected so little cancer in the US 
population.
Fourth, we could not compute 95% 
confidence intervals for the sensitivity pa-
rameters: Because of random noise in the 
simulated predictions and restrictions on 
the sensitivities (sensitivity increases with 
clinical T stage and metastatic state), for-
mal 95% confidence intervals are difficult 
to obtain when using the microsimulation 
model. However, for fixed values of other 
model parameters, the range of plausible 
values for test sensitivity for a local or 
regional stage tumor in clinical stage T3 
(ie, in state T3M0) was narrow (0.24–0.29). 
The range of plausible values contains with 
near certainty a standard computed 95% 
confidence interval. The calculation of the 
range of plausible values is presented in 
Supplementary Figure 2 (available online).
In conclusion, PSA screening in the 
United States did not detect as many pros-
tate cancers as PSA screening in ERSPC–
Affiliations of authors: Department of Public 
Health (EMW, GD, EAMH, RB, SJO, HJdeK) and 
Department of Urology (MJR), Erasmus Medical 
Center, Rotterdam, the Netherlands.
Rotterdam because of the lower sensitivity 
of PSA testing followed by a biopsy. The 
consequence of this lower test sensitivity is 
that the effects of PSA screening in the 
United States are likely to be different from 
those observed in the ERSPC–Rotterdam. 
For example, Draisma et al. (12) noted that 
the lead time (time by which screening ad-
vances diagnosis) and the frequency of 
overdiagnosis were smaller in the United 
States than in ERSPC–Rotterdam (mean 
non-overdiagnosed lead time: 6.9 vs 7.9 
years; overdiagnosis frequency: 42% vs 
66%), indicating that the harms of PSA 
testing in the United States, although still 
substantial, are likely to be less than those 
in the ERSPC–Rotterdam. The benefits of 
PSA screening in the United States are also 
likely to be different from those in ERSPC–
Rotterdam. The ERSPC trial has shown 
that screening for prostate cancer by using 
PSA tests can reduce prostate cancer mor-
tality (4); however, we cannot directly 
translate these mortality reductions to the 
US population because of differences 
between the two populations, such as the 
lower sensitivity of PSA screening in the 
United States. Finally, this analysis also 
shows quantitatively that it is likely that 
there is a difference in the sensitivity of the 
PSA screening (PSA test followed by a bi-
opsy) in the ERSPC and PLCO trials, 
which is likely to have contributed to the 
different outcomes of the trials.
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